The Research Scholars Program supports innovative basic and clinical research from emerging investigators around the world to incorporate new perspectives in our pursuit of scientific understanding and progress. We believe that new voices and research topics are needed to advance scientific knowledge in areas of unmet medical need and create a healthier world.
Since 2008, Gilead’s Research Scholars Program has invested more than $31 million USD into meaningful research conducted by more than 240 scholars to help transform scientific understanding, address knowledge gaps and drive medical breakthroughs.
The program provides financial support to the institutions of 4 early career researchers for a two year period. Each award is funded up to $180,000 USD (inclusive of any indirect costs), to be paid in annual instalments of up to $90,000 USD per year for two years. Funding for the second year is contingent upon submission of a progress report by each early career researcher and approval by the Chair of the Scientific Review Committee which oversees the program.
Recipients of these competitive awards under the program will be selected by a Committee comprised of leaders in the field of Hematologic Malignancies (the "Scientific Review Committee" or the "Committee"). The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, and innovation. Announcement of Award Recipients will be made at an awards acknowledgement session hosted by the Committee and senior representatives from Gilead.
Applicants must meet the eligibility criteria in order to be considered for an award.
- GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. Kite and the Kite Logo are registered trademarks of Kite, a Gilead company. © 2022 Gilead Sciences, Inc. All rights reserved.
- November 2022, IHQ-UNB-2912